Dataset Information

Predictors of sustained drug-free diabetes remission over 48?weeks following short-term intensive insulin therapy in early type 2 diabetes.

ABSTRACT: In early type 2 diabetes (T2DM), short-term intensive insulin therapy (IIT) for 2-4?weeks can decrease insulin resistance, reduce glucagonemia, improve ?-cell function, and even induce a remission of diabetes that can last up to 1?year in some patients. However, little is known about the predictors of such a sustained remission.We evaluated data from the placebo arm of a double-blind randomized controlled trial in which patients with early T2DM (?7?years duration) underwent 4?weeks of IIT (basal detemir, bolus aspart), followed by placebo therapy for 48?weeks (n=25). Participants underwent an oral glucose tolerance test every 12?weeks, enabling serial assessment of insulin sensitivity, ?-cell response, and ?-cell function. Diabetes remission was defined as A1c<6.5% on no medication for T2DM.At 48?weeks post-IIT, 56% of the participants remained in remission. Comparison of remitters to non-remitters revealed no differences in waist, body mass index, insulin sensitivity (Matsuda index), or glucagon profile, either at baseline or over 48?weeks. Compared to non-remitters, the remission group had lower baseline A1c (p=0.006) and better baseline ?-cell function (Insulin Secretion-Sensitivity Index-2) (p=0.01) that was then sustained across 48?weeks post-IIT (p=0.006). On logistic regression analyses, however, shorter duration of diabetes supplanted baseline A1c (p=0.24) and ?-cell function (p=0.19) as an independent predictor of remission (p=0.04). In particular, diabetes duration <2?years predicted persistence of remission (p=0.006).The key determinant of the likelihood of inducing sustained drug-free diabetes remission with short-term IIT is early intervention, particularly within the first 2?years after diagnosis.ClinicalTrials.Gov NCT01270789; Post-results.

SUBMITTER: Kramer CK

PROVIDER: S-EPMC4985916 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes.

Kramer Caroline K CK Zinman Bernard B Choi Haysook H Retnakaran Ravi R

BMJ open diabetes research & care 20160801 1

<h4>Objective</h4>In early type 2 diabetes (T2DM), short-term intensive insulin therapy (IIT) for 2-4 weeks can decrease insulin resistance, reduce glucagonemia, improve β-cell function, and even induce a remission of diabetes that can last up to 1 year in some patients. However, little is known about the predictors of such a sustained remission.<h4>Methods</h4>We evaluated data from the placebo arm of a double-blind randomized controlled trial in which patients with early T2DM (≤7 years duratio ...[more]

PMID: 27547422

Similar Datasets

Project description:IntroductionAchievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP) treatment, and subsequent maintenance of remission following CZP dose continuation, dose reduction or withdrawal. Here, we report outcomes from the first 48 weeks (induction period) of C-OPTIMISE, during which patients received open-label CZP.MethodsC-OPTIMISE (NCT02505542) was a two-part, multicenter, phase 3b study in adult patients with early axSpA (r-/nr-axSpA), including a 48-week open-label induction period followed by a 48-week maintenance period. Patients with active adult-onset axSpA, < 5 years' symptom duration, and fulfilling Assessment of SpondyloArthritis international Society classification criteria, were included. During the induction period, patients received a loading dose of CZP 400 mg at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks (Q2W) up to week 48. The main outcome of the 48-week induction period was the achievement of sustained clinical remission (defined as an Ankylosing Spondylitis Disease Activity Score [ASDAS] < 1.3 at week 32 and < 2.1 at week 36 [or vice versa], and < 1.3 at week 48).ResultsIn total, 736 patients (407 with r-axSpA, 329 with nr-axSpA) were enrolled into the study. At week 48, 43.9% (323/736) of patients achieved sustained remission, including 42.8% (174/407) of patients with r-axSpA and 45.3% (149/329) with nr-axSpA. Patients also demonstrated substantial improvements in axSpA symptoms, MRI outcomes and quality of life measures. Adverse events occurred in 67.9% (500/736) of patients, of which 6.0% (44/736) were serious.ConclusionsOver 40% of patients with early axSpA achieved sustained remission during 48 weeks of open-label CZP treatment. Additionally, patients across the axSpA spectrum demonstrated substantial improvements in imaging outcomes and quality of life following treatment. No new safety signals were identified.Trial registrationNCT02505542.

Dataset Information

Predictors of sustained drug-free diabetes remission over 48?weeks following short-term intensive insulin therapy in early type 2 diabetes.

Publications

Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets